Bank of America
MACK

Bank of America’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Bank of America’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,964
Closed -$58.5K – 8596
2024
Q1 		$58.5K Sell
3,964
-8,560
-68% -$120K ﹤0.01% 6460
2023
Q4 		$168K Buy
12,524
+6,470
+107% +$81.8K ﹤0.01% 6165
2023
Q3 		$74.6K Buy
6,054
+2,239
+59% +$27.1K ﹤0.01% 6369
2023
Q2 		$46.9K Buy
3,815
+2,322
+156% +$29K ﹤0.01% 6481
2023
Q1 		$18.3K Sell
1,493
-186
-11% -$2.19K ﹤0.01% 6777
2022
Q4 		$19.2K Buy
1,679
+143
+9% +$1.18K ﹤0.01% 6752
2022
Q3 		$6K Hold
1,536
– – ﹤0.01% 7379
2022
Q2 		$9K Buy
1,536
+300
+24% +$1.69K ﹤0.01% 7450
2022
Q1 		$8K Sell
1,236
-21
-2% -$118 ﹤0.01% 7809
2021
Q4 		$5K Sell
1,257
-745
-37% -$3.23K ﹤0.01% 7860
2021
Q3 		$10K Buy
2,002
+651
+48% +$3.4K ﹤0.01% 7583
2021
Q2 		$9K Buy
1,351
+35
+3% +$231 ﹤0.01% 7337
2021
Q1 		$8K Buy
1,316
+1
+0.1% +$7 ﹤0.01% 7066
2020
Q4 		$9K Sell
1,315
-122
-8% -$602 ﹤0.01% 6756
2020
Q3 		$6K Sell
1,437
-140
-9% -$514 ﹤0.01% 6574
2020
Q2 		$5K Buy
1,577
+72
+5% +$246 ﹤0.01% 6579
2020
Q1 		$3K Sell
1,505
-1,932
-56% -$5.65K ﹤0.01% 6609
2019
Q4 		$11K Sell
3,437
-1,040
-23% -$4.17K ﹤0.01% 6637
2019
Q3 		$20K Sell
4,477
-646
-13% -$3.23K ﹤0.01% 6587
2019
Q2 		$24K Buy
5,123
+170
+3% +$805 ﹤0.01% 6532
2019
Q1 		$27K Buy
4,953
+3,177
+179% +$14.6K ﹤0.01% 6420
2018
Q4 		$5K Sell
1,776
-213
-11% -$739 ﹤0.01% 6785
2018
Q3 		$8K Sell
1,989
-28,213
-93% -$119K ﹤0.01% 6742
2018
Q2 		$117K Buy
30,202
+10,005
+50% +$66.4K ﹤0.01% 5719
2018
Q1 		$128K Buy
20,197
+15,592
+339% +$129K ﹤0.01% 5611
2017
Q4 		$37K Sell
4,605
-9,803
-68% -$91.4K ﹤0.01% 6199
2017
Q3 		$165K Buy
14,408
+1,727
+14% +$18.2K ﹤0.01% 5476
2017
Q2 		$123K Buy
12,681
+6,967
+122% +$142K ﹤0.01% 5526
2017
Q1 		$139K Sell
5,714
-780
-12% -$19.5K ﹤0.01% 5484
2016
Q4 		$208K Sell
6,494
-14,106
-68% -$602K ﹤0.01% 5308
2016
Q3 		$1.03M Buy
20,600
+12,864
+166% +$534K ﹤0.01% 4144
2016
Q2 		$328K Buy
7,736
+5,232
+209% +$285K ﹤0.01% 4938
2016
Q1 		$165K Sell
2,504
-3,028
-55% -$158K ﹤0.01% 5233
2015
Q4 		$343K Buy
5,532
+1,745
+46% +$123K ﹤0.01% 5050
2015
Q3 		$254K Sell
3,787
-7,933
-68% -$647K ﹤0.01% 5213
2015
Q2 		$1.14M Buy
11,720
+7,669
+189% +$730K ﹤0.01% 3993
2015
Q1 		$379K Sell
4,051
-1,030
-20% -$87.7K ﹤0.01% 4499
2014
Q4 		$452K Sell
5,081
-869
-15% -$63.3K ﹤0.01% 4709
2014
Q3 		$411K Sell
5,950
-32,366
-84% -$1.73M ﹤0.01% 4772
2014
Q2 		$2.2M Buy
38,316
+3,148
+9% +$160K ﹤0.01% 3282
2014
Q1 		$1.4M Sell
35,168
-4,006
-10% -$171K ﹤0.01% 3571
2013
Q4 		$1.64M Sell
39,174
-25,279
-39% -$733K ﹤0.01% 3518
2013
Q3 		$1.92M Sell
64,453
-107,881
-63% -$3.77M ﹤0.01% 3317
2013
Q2 		$9.14M Buy
+172,334
New +$7.55M ﹤0.01% 1792

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America's MACK Position: Q2 2024 in Review

Bank of America sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 3,964 shares — an estimated $58.5K sold.

Bank of America first reported a position in MACK in Q2 2013 and held it in 44 quarters. The position peaked at $9.14M in Q2 2013. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • Bank of America reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Bank of America sold 3,964 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $58.5K.
  • Bank of America first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 44 quarters.
  • Bank of America's Merrimack Pharmaceuticals, Inc. position peaked at $9.14M in Q2 2013.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Bank of America's 13F filing for Q2 2024, filed 14 Aug 2024.